| human | Q5 |
| P6178 | Dimensions author ID | 01047447607.98 |
| P6634 | LinkedIn personal profile ID | vesa-kataja-4a19a794 |
| P1207 | NUKAT ID | n2016014236 |
| P496 | ORCID iD | 0000-0003-4846-4843 |
| P10861 | Springer Nature person ID | 01047447607.98 |
| P214 | VIAF ID | 139148207879100341530 |
| P7859 | WorldCat Identities ID (superseded) | viaf-139148207879100341530 |
| P27 | country of citizenship | Finland | Q33 |
| P69 | educated at | University of Kuopio | Q9091642 |
| P108 | employer | Central Finland Hospital District | Q11871077 |
| Kuopio University Hospital | Q11873596 | ||
| P734 | family name | Kataja | Q27941034 |
| Kataja | Q27941034 | ||
| Kataja | Q27941034 | ||
| P735 | given name | Vesa | Q10714568 |
| Vesa | Q10714568 | ||
| P106 | occupation | professor | Q121594 |
| medical director | Q256688 | ||
| chief physician | Q1068947 | ||
| P21 | sex or gender | male | Q6581097 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q57278985 | 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q57278922 | A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q45181384 | A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability |
| Q37192589 | A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q46945525 | A novel BRCA2 gene mutation, 4081 insA, in a Finnish breast/ovarian cancer family associated with favourable clinical course |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q57278904 | A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate |
| Q55043120 | A recurrent mutation in PALB2 in Finnish cancer families. |
| Q44443237 | A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. |
| Q57278996 | Acetowhite staining and its significance in diagnosis of oral mucosal lesions in women with genital HPV infections |
| Q34426881 | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial |
| Q50770788 | Add-on device for stereotactic core-needle breast biopsy: how many biopsy specimens are needed for a reliable diagnosis? |
| Q38380059 | Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial |
| Q57278896 | Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial |
| Q43244221 | Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial |
| Q34496969 | Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer |
| Q44358935 | Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. |
| Q57278931 | An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found |
| Q57278975 | An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting |
| Q43772485 | An unexplained cancer disease and bone metastases |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q53399411 | Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57278901 | Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57278905 | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q35683537 | Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q39105713 | Burden of Prostate Cancer and Future Need for Health Care Services |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q57278920 | CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population |
| Q57278961 | Cancer Incidence in Hypertensive Patients in North Karelia, Finland |
| Q49935307 | Cancer costs and outcomes for common cancer sites in the Finnish population between 2009-2014. |
| Q38684256 | Cancer costs and outcomes in the Finnish population 2004-2014. |
| Q43843779 | Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q57278987 | Comparison of Ondansetron with Customary Treatment in the Prophylaxis of Nausea and Emesis Induced by Non-Cisplatin Containing Chemotherapy |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q39889502 | Current and predicted cost of metastatic renal cell carcinoma in Finland |
| Q33801758 | Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer |
| Q51984177 | Diet and the risk of breast cancer in a case-control study: does the threat of disease have an influence on recall bias? |
| Q46157405 | Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial |
| Q47365717 | Does the outcome of prostate cancer patients with large prostates differ from small prostate size in permanent seed, low dose-rate brachytherapy? |
| Q57278933 | ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of esophageal cancer |
| Q57278936 | ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer |
| Q57278937 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer |
| Q57278938 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer |
| Q57278940 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer |
| Q57278950 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer |
| Q57278942 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer |
| Q57278944 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN) |
| Q57278946 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma |
| Q29038654 | ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV) |
| Q40308453 | Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. |
| Q44004588 | Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland |
| Q57278923 | Effective palliation without normal tissue toxicity using low-dose ultrafractionated re-irradiation for tumor recurrence after radical or adjuvant radiotherapy |
| Q57278979 | Effects of granisetron with doxorubicin or epirubicin on ECG intervals |
| Q53201010 | Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy--morbidity and outcome results. |
| Q44175947 | Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q40476877 | European collaborative group on prostate brachytherapy: preliminary report in 1175 patients. |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q47345941 | Expression of HER2 and its association with AP-2 in breast cancer |
| Q34372081 | Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q57278974 | Flow cytometric analysis of tumor DNA profile related to response to treatment and survival in small-cell lung cancer |
| Q43250043 | Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial |
| Q57278925 | Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q57278924 | Generalisability of survival estimates for patients with breast cancer – A comparison across two population-based series |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
| Q43575811 | Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q36547888 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers |
| Q57278978 | Hypersensitivity reactions associated with 5-hydroxytryptamine3-receptor antagonists: a class effect? |
| Q38780363 | Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q57278912 | Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Q37489176 | Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q57278971 | Inverse Association Between Dietary and Serum Conjugated Linoleic Acid and Risk of Breast Cancer in Postmenopausal Women |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q48624684 | Learning curve for add-on stereotactic core needle breast biopsy. |
| Q57278969 | Lifetime alcohol consumption and breast cancer: a case-control study in Finland |
| Q57278913 | Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Q35889678 | Long-term prognosis of breast cancer detected by mammography screening or other methods |
| Q35642678 | Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q51015419 | Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer. |
| Q36619164 | Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q57278915 | Mixed or non-seminomatous germ-cell tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Q42706074 | MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen |
| Q42438075 | Molecular subtypes of breast cancers detected in mammography screening and outside of screening |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q46567991 | NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer |
| Q45194389 | NAT2 slow acetylator genotype as an important modifier of breast cancer risk |
| Q57278988 | Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System |
| Q46648097 | Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q52069703 | Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. |
| Q57278989 | Ondansetron and Tropisetron with Dexamethasone in the Prophylaxis of Acute Vomiting Induced by Non-cisplatin-Containing Chemotherapy |
| Q37489864 | Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). |
| Q34351474 | Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q57278956 | Pagetic Bone Lesions in a Patient with Early Breast Cancer |
| Q57278997 | Parenteral soya bean fat emulsions potentiate the hepatotoxicity ofE. coli endotoxin in suckling rats |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q27851443 | Penetrance analysis of the PALB2 c.1592delT founder mutation |
| Q53097455 | Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q57278958 | Polymorphic catechol-O-methyltransferase gene and breast cancer risk |
| Q113417005 | Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q57278972 | Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer |
| Q57278993 | Prevalence of Genital Human Papillomavirus Infections in a Mass-Screened Finnish Female Population Aged 20–65 Years |
| Q50551200 | Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. |
| Q37488939 | Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q57278981 | Prognostic Significance of TGF-α Expression in Breast Cancer |
| Q57278991 | Prognostic factors in cervical human papillomavirus infections |
| Q30802558 | Prognostic factors in invasive cervical carcinomas associated with human papillomavirus (HPV). Quantitative data and cytokeratin expression |
| Q30870035 | Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data |
| Q33910297 | Prospective follow-up of genital HPV infections: survival analysis of the HPV typing data |
| Q34620634 | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57278890 | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57278916 | Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Q27022847 | Prostate cancer: ESMO Consensus Conference Guidelines 2012 |
| Q37489171 | Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q47820754 | Radiation-induced changes in skin type I and III collagen synthesis during and after conventionally fractionated radiotherapy |
| Q57278973 | Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study |
| Q48905804 | Recurrences after immediate reconstruction in breast cancer. |
| Q57278953 | Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q28301674 | Refinement of the 22q12-q13 breast cancer--associated region: evidence of TMPRSS6 as a candidate gene in an eastern Finnish population |
| Q57278893 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57278906 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q37489181 | Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q57278983 | Risk Factors Associated with Cervical Human Papillomavirus Infections: A Case-Control Study |
| Q44321888 | Risk for distant recurrence of breast cancer detected by mammography screening or other methods |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q42934843 | ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival |
| Q34307873 | SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer? |
| Q38655027 | Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial |
| Q57278968 | Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer |
| Q57278919 | Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families |
| Q43586259 | Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland |
| Q57278977 | Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer |
| Q37855949 | Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection |
| Q36976208 | Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer |
| Q40731645 | Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. |
| Q57278928 | Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women |
| Q50776665 | Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. |
| Q44516860 | Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report |
| Q43016615 | Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q37489189 | Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q57278891 | Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q34022779 | Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57278917 | Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Q37489185 | Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q36917100 | The UGT1A6_19_GG genotype is a breast cancer risk factor |
| Q57278962 | The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography |
| Q34144358 | The extent of linkage disequilibrium in four populations with distinct demographic histories |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q51625774 | The surgical and oncological safety of immediate breast reconstruction. |
| Q34132450 | The visibility of cancer on previous mammograms in retrospective review. |
| Q39464268 | Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure |
| Q57278970 | Toenail selenium and breast cancer—a case-control study in Finland |
| Q33821467 | Transcription factors zeb1, twist and snai1 in breast carcinoma |
| Q57278883 | Treatment Costs In Primary And Secondary Healthcare In Finland |
| Q43951696 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial |
| Q33910850 | Type II transmembrane serine protease gene variants associate with breast cancer |
| Q57278964 | Validity of radiological examinations of patients with breast cancer in different age groups in a population based study |
| Q57278902 | Very high quantitative tumor HER2 content and outcome in early breast cancer |
| Q44843638 | Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk |
| Q25257811 | XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study |
| Q57278886 | XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer |
| Q57278982 | c-erbB-2 Oncogene Expression in Salivary Gland Tumours |
| Q28534781 | Γ-secretase components as predictors of breast cancer outcome |
Search more.